Avita Medical Shares Drop After 2Q Loss, Guidance Cut

Dow Jones

Aug 08

By Chris Wack

Avita Medical shares dropped 29%, to $3.83, after the company reported a wider-than-expected second-quarter loss and reduced revenue guidance.

The stock hit its 52-week low of $3.60 earlier in the session, and is down 52% in the past 12 months.

The therapeutic wound-care company said it had a second-quarter loss of $9.92 million, or 38 cents a share, compared with a loss of $15.4 million, or 60 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $6.6 million, or 27 cents a share.

Revenue for the quarter was $18.4 million, compared with last year's $15.2 million and the $22.5 million analysts were expecting.

Avita said it saw a significant headwind from a temporary gap in Medicare administrative contractor payments to providers for the use of its flagship Recell System, which it said led to a weakening in demand. The company said multiple Medicare administrative contractors initiated payments in July, with resolution expected in the third quarter.

The Valencia, Calif., company lowered its 2025 revenue guidance to $76 million to $81 million, compared with previous guidance of $100 million to $106 million, as a result of slower-than-expected sale in the first half.

As of June 30, the company had $15.7 million in cash, cash equivalents, and marketable securities.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

August 08, 2025 10:12 ET (14:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557457811"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557457811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557457811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557457811","market":"hk","top_or_hot":-1,"title":"Avita Medical Shares Drop After 2Q Loss, Guidance Cut","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Avita Medical shares dropped 29%, to $3.83, after the company reported a wider-than-expected second-quarter loss and reduced revenue guidance. \n</p>\n<p>\n  The stock hit its 52-week low of $3.60 earlier in the session, and is down 52% in the past 12 months. \n</p>\n<p>\n   The therapeutic wound-care company said it had a second-quarter loss of $9.92 million, or 38 cents a share, compared with a loss of $15.4 million, or 60 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $6.6 million, or 27 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $18.4 million, compared with last year's $15.2 million and the $22.5 million analysts were expecting. \n</p>\n<p>\n  Avita said it saw a significant headwind from a temporary gap in Medicare administrative       contractor payments to providers for the use of its flagship Recell System, which it said led to a weakening in demand. The company said multiple Medicare administrative contractors initiated payments in July, with resolution expected in the third quarter. \n</p>\n<p>\n  The Valencia, Calif., company lowered its 2025 revenue guidance to $76 million to $81 million, compared with previous guidance of $100 million to $106 million, as a result of slower-than-expected sale in the first half. \n</p>\n<p>\n  As of June 30, the company had $15.7 million in cash, cash equivalents, and marketable securities. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 08, 2025 10:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avita Medical Shares Drop After 2Q Loss, Guidance Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvita Medical Shares Drop After 2Q Loss, Guidance Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-08 22:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Avita Medical shares dropped 29%, to $3.83, after the company reported a wider-than-expected second-quarter loss and reduced revenue guidance. \n</p>\n<p>\n  The stock hit its 52-week low of $3.60 earlier in the session, and is down 52% in the past 12 months. \n</p>\n<p>\n   The therapeutic wound-care company said it had a second-quarter loss of $9.92 million, or 38 cents a share, compared with a loss of $15.4 million, or 60 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $6.6 million, or 27 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $18.4 million, compared with last year's $15.2 million and the $22.5 million analysts were expecting. \n</p>\n<p>\n  Avita said it saw a significant headwind from a temporary gap in Medicare administrative       contractor payments to providers for the use of its flagship Recell System, which it said led to a weakening in demand. The company said multiple Medicare administrative contractors initiated payments in July, with resolution expected in the third quarter. \n</p>\n<p>\n  The Valencia, Calif., company lowered its 2025 revenue guidance to $76 million to $81 million, compared with previous guidance of $100 million to $106 million, as a result of slower-than-expected sale in the first half. \n</p>\n<p>\n  As of June 30, the company had $15.7 million in cash, cash equivalents, and marketable securities. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 08, 2025 10:12 ET (14:12 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2557457811","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557457811","pubTimestamp":1754662320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Avita Medical shares dropped 29%, to $3.83, after the company reported a wider-than-expected second-quarter loss and reduced revenue guidance.The stock hit its 52-week low of $3.60 earlier in the session, and is down 52% in the past 12 months.The therapeutic wound-care company said it had a second-quarter loss of $9.92 million, or 38 cents a share, compared with a loss of $15.4 million, or 60 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $6.6 million, or 27 cents a share.Revenue for the quarter was $18.4 million, compared with last year's $15.2 million and the $22.5 million analysts were expecting.Avita said it saw a significant headwind from a temporary gap in Medicare administrative       contractor payments to providers for the use of its flagship Recell System, which it said led to a weakening in demand. The company said multiple Medicare administrative contractors initiated payments in July, with resolution expected in the thir","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RCEL":"Avita Medical Ltd."},"translate_title":"阿维塔医疗股价在第二季度亏损后下跌，指引下调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCEL":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Avita Medical shares dropped 29%, to $3.83, after the company reported a wider-than-expected second-quarter loss and reduced revenue guidance. \n\n\n  The stock hit its 52-week low of $3.60 earlier in the session, and is down 52% in the past 12 months. \n\n\n   The therapeutic wound-care company said it had a second-quarter loss of $9.92 million, or 38 cents a share, compared with a loss of $15.4 million, or 60 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $6.6 million, or 27 cents a share. \n\n\n  Revenue for the quarter was $18.4 million, compared with last year's $15.2 million and the $22.5 million analysts were expecting. \n\n\n  Avita said it saw a significant headwind from a temporary gap in Medicare administrative       contractor payments to providers for the use of its flagship Recell System, which it said led to a weakening in demand. The company said multiple Medicare administrative contractors initiated payments in July, with resolution expected in the third quarter. \n\n\n  The Valencia, Calif., company lowered its 2025 revenue guidance to $76 million to $81 million, compared with previous guidance of $100 million to $106 million, as a result of slower-than-expected sale in the first half. \n\n\n  As of June 30, the company had $15.7 million in cash, cash equivalents, and marketable securities. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 08, 2025 10:12 ET (14:12 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}